12 Hot Penny Stocks to Invest in Right Now

Page 8 of 10

3. Opus Genetics, Inc. (NASDAQ:IRD)

3-Month Performance as of November 25: 72.17%

Average Upside Potential as of November 24: 285.50%

Number of Hedge Fund Holders: 6

Opus Genetics, Inc. (NASDAQ:IRD) is one of the 12 hot penny stocks to invest in right now.

On November 25, 2025, The Fly reported that Piper Sandler initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an “Overweight” rating and a $7 price target. The investment firm highlighted OPGx-LCA5, the company’s lead gene therapy program. The program aims to treat Leber congenital amaurosis type 5 (LCA5), a condition that currently has no available treatment options. At the same time, the company’s second program, OPGx-BEST1, which targets BEST1-related inherited retinal diseases, also boasts encouraging preclinical data, boosting the investment firm’s confidence.

Earlier, on November 12, Opus Genetics, Inc. (NASDAQ:IRD) reported Q3 2025 results. The quarter saw its net loss widen to $17.5 million from $7.5 million in the prior-year quarter. This was driven by changes in the fair value of warrants. Furthermore, the company noted significant progress in its gene therapy pipeline, including positive Phase 1/2 data for OPGx-LCA5, which showed significant improvements in vision for pediatric patients.

During the quarter, the company also reported the successful completion of a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the U.S. Food and Drug Administration (FDA). The management believes this completion will enhance the potential for an accelerated regulatory pathway to OPGx-LCA5 approval. Opus Genetics, Inc. (NASDAQ:IRD) also completed a $23 million equity offering, expected to provide financial support for advancing the company’s clinical trials, including the ongoing Phase ½ trial for OPGx-BEST1.

Opus Genetics, Inc. (NASDAQ:IRD) is focused on the development of gene therapies to restore vision in patients with inherited retinal diseases.

Page 8 of 10